Abstracts tagged "autoimmune diseases"

Abstract Number: 3158 • 2015 ACR/ARHP Annual Meeting
Impact of Family History of Systemic Lupus Erythematosus on Risk of Autoimmune Diseases: National Cohort Study in Denmark 1977-2012
Constance Jensina Ulff-Møller¹, Jacob Simonsen², Søren Jacobsen¹ and Morten Frisch², ¹Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ²Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease (AID), which develops through the interplay of genetic, epigenetic and environmental factors and may cluster…
Abstract Number: 387 • 2015 ACR/ARHP Annual Meeting
Features of 847 Childhood-Onset Systemic Lupus Erythematousus Patients in Three Age-Related Groups at Diagnosis: A Brazilian Multicenter Study
Clovis A Silva¹, Roberta C. Gomes Sr.², Marco F. Silva³, Katia T. Kozu⁴, Eloisa Bonfá⁵, Rosa M R Pereira⁶, Maria Teresa Terreri⁷, Claudia S. Magalhães Sr.⁸, Silvana B. Sacchetti Sr.⁹, Roberto Marini Sr.¹⁰, Melissa Fraga¹¹, Luciana M. Carvalho Sr.¹², Cássia M. Barbosa¹³ and Magda Carneiro-Sampaio Sr.¹⁴, ¹Pediatric Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ²Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology Unit-Children’s Institute,, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁴Pediatrics, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁵Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁶Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁷Pediatrics, Universidade Federal de Sao Paulo, São Paulo, Brazil, ⁸Pediatric Rheumatology Unit, São Paulo State University – Faculdade de Medicina de Botucatu, São Paulo, Brazil, ⁹Pediatric Rheumatology Unit, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil, ¹⁰Pediatric Rheumatology Unit, State University of Campinas, São Paulo, Brazil, ¹¹Pediatrics, Universidade Federal de São Paulo / UNIFESP, São Paulo, Brazil, ¹²Pediatric Rheumatology Unit, Ribeirão Preto Medical School – University of São Paulo, São Paulo, Brazil, ¹³Pediatric Rheumatology Unit, Hospital Infantil Darcy Vargas, São Paulo, Brazil, ¹⁴Pediatric Allergology and Immunology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Previous retrospective evaluations suggested that age at diagnosis may influence disease expression in terms of initial clinical presentation, pattern of organ involvement and serological…
Abstract Number: 826 • 2015 ACR/ARHP Annual Meeting
Systemic Sclerosis Inpatient Mortality Has Not Improved from 1995-2011. Results from a National Irish Audit of Scleroderma Co-Morbidities.
Len Harty¹, Deirdre Fitzgerald², Michael Henry², John Ryan³ and Sinead Harney³, ¹Cork University Hospital, Cork, Ireland, ²Respiratory, Cork University Hospital, Cork, Ireland, ³Rheumatology, Cork University Hospital, Cork, Ireland
Background/Purpose: Despite the advent of potent immunosuppressive and vasoactive therapies it is not clear that longevity of patients with systemic sclerosis (SSc) has improved. Therefore…
Abstract Number: 1033 • 2015 ACR/ARHP Annual Meeting
Novel Ligand-Independent Peptide Inhibitors of Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) and T Cell Receptor (TCR): Efficacy in a Collagen-Induced Arthritis Model Suggests New Targeted Treatment for Rheumatoid Arthritis
Zu T. Shen and Alexander B. Sigalov, SignaBlok, Inc., Shrewsbury, MA
Background/Purpose: Macrophages and T cells are central to the pathophysiology of autoimmune diseases. Synovial macrophages, synovial fibroblasts and infiltrating T lymphocytes are the most abundant…
Abstract Number: 1224 • 2015 ACR/ARHP Annual Meeting
Infection Rate in HIV Patients Who Received TNF-a Inhibitor Therapy for Concomitant Autoimmune Diseases
Sintawat Wangsiricharoen¹, Colin Ligon², Ahmad Dehrab³, Lydia Gedmintas⁴, Marisa Tungsiripat⁵, Clifton Bingham⁶, Carlos J. Lozada⁷ and Leonard H. Calabrese⁸, ¹Chiang Mai University, Chiang Mai, Thailand, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, University of Miami Jackson Memorial Hospital, Miami, FL, ⁴Rheumatology, Brigham's Women's Hospital, Boston, MA, ⁵Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, ⁶Johns Hopkins University, Baltimore, MD, ⁷University of Miami Miller School of Medicine, Miami, FL, ⁸Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Few HIV-infected patients have been treated with tumor necrosis factor (TNF)-α inhibitor therapy for autoimmune diseases refractory to conventional therapies. Evidence supporting the safety…
Abstract Number: 1356 • 2015 ACR/ARHP Annual Meeting
Autoimmune Manifestations in Hepatitis C: A Single-Centered Experience
Azza Ali¹, Reshma Khan¹, Kirthi Lilley², Paul Naylor², Rajaie Namas¹ and Malini Venkatram¹, ¹Rheumatology, Wayne State University, Detroit, MI, ²Gastroenterology, Wayne State University, Detroit, MI
Background/Purpose: Hepatitis C infection (HCV) is a leading cause of chronic liver disease. It is associated with a plethora of autoimmune manifestations including clinical, serological…
Abstract Number: 1416 • 2015 ACR/ARHP Annual Meeting
Postoperative Complications Rate in Orthopaedic Surgery Performed in Rheumatic Patients in Use of Biologic Agents
Clarissa Queiroz Pimentel¹, Luiz Eduardo de Paula¹, Ana Paula Luppino-Assad², Gilberto Luis Camanho³, Eloisa Bonfá⁴ and Marco Antonio Gonçalves Pontes Filho¹, ¹Division of Rheumatology, University of São Paulo Medical School, São Paulo, Brazil, ²Division of Rheumatology, University of São Paulo, sao paulo, Brazil, ³Division of Orthopedics, University of São Paulo Medical School, São Paulo, Brazil, ⁴Rheumatology, University of São Paulo, São Paulo, Brazil, Sao Paulo, Brazil
Background/Purpose: Biologic agents have been associated with an increased risk of infection, thrombosis and delayed wound healing. However, there is no definitive consensus on suspension…
Abstract Number: 1512 • 2015 ACR/ARHP Annual Meeting
Incidence of Co-Morbid Autoimmune Diseases in Patients with Rheumatoid Arthritis
TA Simon¹, H Kawabata¹, JM Esdaile², V Moorthy³ and S Suissa⁴, ¹Bristol-Myers Squibb, Hopewell, NJ, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Mu Sigma, Northbrook, IL, ⁴McGill University, Montreal, QC, Canada
Background/Purpose: Rheumatoid arthritis (RA) is one of more than 80 different types of autoimmune diseases, many of which, including RA, share common pathogenic mechanisms, resulting…
Abstract Number: 1359 • 2014 ACR/ARHP Annual Meeting
Care of Women with Rheumatological Conditions during Family Planning and Pregnancy
Megan E. B. Clowse¹, Munther Khamashta², Daphnee S. Pushparajah³ and Eliza Chakravarty⁴, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Graham Hughes Lupus Research Laboratory, The Rayne Institute, London, United Kingdom, ³UCB Pharma, Brussels, Belgium, ⁴OMRF, Oklahoma City, OK
Background/Purpose Rheumatological diseases often affect women of reproductive age and can impact pregnancy outcomes. There is a need to understand how patients (pts) are managed…
Abstract Number: 1073 • 2014 ACR/ARHP Annual Meeting
Prescription Medication Trends in Medicaid-Enrolled Pregnant Women with Rheumatoid Arthritis, Psoriasis, and Systemic Lupus Erythematosus
Rishi Desai¹, Krista Huybrechts², Brian Bateman², Helen Mogun², Sonia Hernandez-diaz³ and Seoyoung C. Kim⁴, ¹PharmacoEpidemiology & PharmacoEconomics, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ³Harvard School of Public Health, Boston, MA, ⁴Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Little is known about the trends of medication use in pregnant women with autoimmune disorders. The objective of the current study was to…
Abstract Number: 845 • 2014 ACR/ARHP Annual Meeting
The Risk of Cancer with Tumor Necrosis Factor Inhibitors in Patients Concomitantly Exposed to Non-Biological Immunosuppressants Differs According to the Indication
Layla Saliba¹, Guillaume Moulis², Malak Aboutaam³, Grégory Pugnet², Vanessa Rousseau¹, Leila Chebane¹, Nadine Petitpain⁴, Bernadette Baldin⁵, Jean-Louis Montastruc¹ and Haleh Bagheri¹, ¹Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, Toulouse, France, ²Toulouse University Hospital, Department of Internal Medicine, University of Toulouse, INSERM UMR 1027, Toulouse, France, ³Reims University Hospital, Pharmacovigilance Regional Center, Reims, France, ⁴Nancy University Hospital, Pharmacovigilance Regional Center, Nancy, France, ⁵Nice University Hospital, Pharmacovigilance Regional Center, Nice, France
Background/Purpose: The risk of cancer with TNF-a inhibitor (TNFi) in patients concomitantly exposed to non-biological immunosuppressants (NBIS) is highly debated in RA, AS and psoriasis/PsA.…
Abstract Number: 525 • 2014 ACR/ARHP Annual Meeting
The Genetic Basis of Sjögren’s Syndrome (SS) Clinical Manifestations from Genome-Wide Association Analysis of Subphenotype Extremes in an International Cohort
Lindsey A. Criswell¹, Kimberly E. Taylor^2,3, Quenna Wong⁴, David M. Levine⁴, Caitlin McHugh⁴, Cathy Laurie⁴, Kimberly Doheny⁵, Mi Y. Lam⁶, Alan N. Baer⁷, Stephen Challacombe⁸, Yi Dong⁹, Hector Lanfranchi¹⁰, Morten Schiødt¹¹, M. Srinivasan¹², Susumu Sugai¹³, Hisanori Umehara¹⁴, Frederick B. Vivino¹⁵, Zhao Yan¹⁶, Stephen Shiboski¹⁷, Troy Daniels¹⁸, John S. Greenspan⁶, Caroline H. Shiboski⁶ and Sjögren's Syndrome Collaborative Clinical Alliance (SICCA)¹⁹, ¹Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ²Medicine, University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁴University of Washington, Biostatistics, Seattle, WA, ⁵Center for Inherited Disease Research, Baltimore, MD, ⁶Orofacial Sciences, University of California San Francisco, San Francisco, CA, ⁷Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Kings College London, London, United Kingdom, ⁹Dept of Rheumatology, Peking Univ Med Coll Hospital, East City Beijing, China, ¹⁰University of Buenos Aires, Buenos Aires, Argentina, ¹¹Oral and Maxillofacial Surgery, Rigshospitalet, Copenhagen, Denmark, ¹²Aravind Eye Hospital, Madurai, India, ¹³Kanazawa Medical University, Ishikawa, Japan, ¹⁴Internal Medicine, Division of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan, ¹⁵Medicine, Penn Presbyt Med Ctr, Philadelphia, PA, ¹⁶Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, ¹⁷Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, ¹⁸Orofacial Sciences, Box 0422, University of California San Francisco, San Francisco, CA, ¹⁹University of California San Francisco, San Francisco, CA
Background/Purpose Our goal is to define the contribution of genetic factors to two hallmark manifestations of SS, keratoconjunctivitis sicca (KCS) and focal lymphocytic sialadenitis (FLS),…
Abstract Number: 233 • 2014 ACR/ARHP Annual Meeting
Significance of Serum Marker Levels of Wnt/ß-Catenin Signaling Pathway in Patients with Systemic Autoimmune Diseases Under Glucocorticoid Therapy; A Prospective Study
Mai Kawazoe, Kotaro Shikano, Kaichi Kaneko, Shotaro Masuoka, Hiroshi Sato, Emiko Shindo, Natsuki Fujio, Sei Muraoka, Makoto Kaburaki, Nahoko Tanaka, Tatsuhiro Yamamoto, Kenji Takagi, Natsuko Kusunoki, Tomoko Hasunuma and Shinichi Kawai, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
Background/Purpose: Glucocorticoids are widely used to treat a variety of diseases, including systemic autoimmune diseases. Although glucocorticoids improve the outcome for patients with these diseases,…
Abstract Number: L4 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Sifalimumab, an Anti IFN-Alpha Monoclonal Antibody, in a Phase 2b Study of Moderate to Severe Systemic Lupus Erythematosus (SLE)
Munther Khamashta^1,2, Joan T. Merrill³, Victoria P. Werth^4,5, Richard Furie⁶, Kenneth Kalunian⁷, Gabor G. Illei⁸, Jorn Drappa⁸, Liangwei Wang⁸ and Warren Greth⁸, ¹Division of Women's Health, Graham Hughes Lupus Research Laboratory, King's College London, London, United Kingdom, ²Lambeth Wing, The Rayne Institute, St Thomas' Hospital London, London, United Kingdom, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Philadelphia VA Medical Center, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶North Shore-LIJ Health System, Lake Success, NY, ⁷UCSD School of Medicine, La Jolla, CA, ⁸MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Efficacy and safety of sifalimumab were assessed in a Phase 2b, randomized, double-blind, placebo (PBO)-controlled study in subjects with SLE (NCT01283139). Methods: Adults (n=431)…
Abstract Number: 2956 • 2014 ACR/ARHP Annual Meeting
Identification of Autoimmune Functional Variants Under Positive Selection in the Gullah African American Population of South Carolina
Paula S. Ramos¹, Satria Sajuthi², Jasmin Divers², Yiqi Huang³, Uma Nayak⁴, Wei-Min Chen⁴, Kelly J. Hunt⁵, Diane L. Kamen⁶, Gary S. Gilkeson⁶, Jyotika K. Fernandes⁷, Ida J. Spruill⁷, W. Timothy Garvey⁸, Michèle M. Sale³ and Carl D. Langefeld², ¹Department of Medicine, Medical University of South Carolina, Charleston, SC, ²Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ³Department of Medicine and Center for Public Health Genomics, University of Virginia, Charlottesville, VA, ⁴Public Health Sciences, University of Virginia, Charlottesville, VA, ⁵Public Health Sciences, Medical University of South Carolina, Charleston, SC, ⁶Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁷Medical University of South Carolina, Charleston, SC, ⁸Department of Nutrition Sciences and Birmingham VA Medical Center, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose The reasons for the ethnic disparities in rheumatologic and autoimmune diseases (ADs) are largely unknown. We posit that population-specific selection influencing the allele frequencies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].